Incyte reported $5.36B of revenue over the trailing twelve months, +21% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $5.36B (to Q1 2026). Net income: $1.43B, trailing twelve months to Q1 2026. Operating margin: 31%, trailing twelve months to Q1 2026. EPS: $7.08, trailing twelve months to Q1 2026.

INCYIncyte

Healthcare

$112.81+31% 1Y

$112.81

$81.6652 weeks$129.88

INCY as reported

Incyte reported $5.36B of revenue over the trailing twelve months, +21% on the year before. 10 reported series are charted on this page, each one as filed.

$5.36B

Revenue, trailing twelve months · to Q1 2026 · +21% against the twelve months before

Net income: $1.43B
Net income · +6631% year on year · trailing twelve months to Q1 2026
Operating margin: 31%
Operating margin · trailing twelve months to Q1 2026
EPS: $7.08
EPS · +2732% year on year · trailing twelve months to Q1 2026

Details›

Every series Ryufin has for INCY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$5.36B	+21%	Q1 2026
Net income	$1.43B	+6631%	Q1 2026
EPS	$7.08	+2732%	Q1 2026
Gross margin	93%	n/a	Q1 2026
Operating margin	31%	n/a	Q1 2026
Net margin	27%	n/a	Q1 2026
ROE	24%	n/a	Q1 2026
ROA	18%	n/a	Q1 2026
Free cash flow	$892M	n/a	Q4 2022 · 13 quarters behind
P/E	15.9	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.